Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
Velasco, Roser (Universitat Autònoma de Barcelona. Institut de Neurociències)
Alemany, Montserrat (Institut d'Investigació Biomèdica de Bellvitge)
Villagrán, Macarena (Institut d'Investigació Biomèdica de Bellvitge)
Argyriou, Andreas A. (Neurology Department, "Saint Andrew's" State General Hospital of Patras)

Fecha:	2021
Resumen:	Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.
Ayudas:	Instituto de Salud Carlos III PI20/00283
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Neurotoxicity ; Oxaliplatin ; Chemotherapy-induced peripheral neuropathy ; Biomarker ; Genomics ; Neuropathy ; FOLFOX ; FOLFIRINOX ; XELOX ; Gastrointestinal cancer
Publicado en:	Journal of personalized medicine, Vol. 11 (july 2021) , ISSN 2075-4426

DOI: 10.3390/jpm11070669
PMID: 34357136

21 p, 1.3 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados